

# Martin Aringer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9322508/publications.pdf>

Version: 2024-02-01

162  
papers

20,734  
citations

38660

50  
h-index

10708

138  
g-index

242  
all docs

242  
docs citations

242  
times ranked

18188  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
3	Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. <i>Cell</i> , 1999, 97, 133-144.	13.5	1,271
4	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
5	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
6	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
7	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	13.9	974
8	Joint European League Against Rheumatism and European Renal Associationâ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
9	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
10	SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. <i>Nature Genetics</i> , 2008, 40, 437-442.	9.4	678
11	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
12	2019 Update of the Joint European League Against Rheumatism and European Renal Associationâ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.5	463
13	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , 2000, 95, 3223-3231.	0.6	356
14	Safety and efficacy of tumor necrosis factor ? blockade in systemic lupus erythematosus: An open-label study. <i>Arthritis and Rheumatism</i> , 2004, 50, 3161-3169.	6.7	317
15	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
16	Ultrasound Therapy for Calcific Tendinitis of the Shoulder. <i>New England Journal of Medicine</i> , 1999, 340, 1533-1538.	13.9	266
17	Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes. <i>Journal of Immunology</i> , 2000, 164, 1768-1774.	0.4	228
18	Role of interleukinâ€“6 in stress, sleep, and fatigue. <i>Annals of the New York Academy of Sciences</i> , 2012, 1261, 88-96.	1.8	208

#	ARTICLE	IF	CITATIONS
19	Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. <i>Journal of Clinical Investigation</i> , 2015, 125, 413-424.	3.9	190
20	Adverse events and efficacy of TNF- $\alpha$ blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , 2009, 48, 1451-1454.	0.9	173
21	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	1.6	170
22	Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation. <i>Journal of Immunology</i> , 2000, 164, 4659-4664.	0.4	168
23	Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 130-136.	1.5	166
24	The role of tumor necrosis factor-alpha in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2008, 10, 202.	1.6	143
25	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	1.5	129
26	"To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 589-598.	1.6	126
27	Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 274-279.	6.7	102
28	Therapeutic blockade of TNF in patients with SLE "Promising or crazy?". <i>Autoimmunity Reviews</i> , 2012, 11, 321-325.	2.5	102
29	High levels of bcl-2 protein in circulating t lymphocytes, but not b lymphocytes, of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1994, 37, 1423-1430.	6.7	101
30	Inflammatory markers in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 110, 102374.	3.0	100
31	The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 966-969.	0.5	98
32	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
33	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019, 71, 91-98.	2.9	93
34	Activation of the interferon- $\gamma$ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. <i>Arthritis and Rheumatism</i> , 2009, 60, 1463-1471.	6.7	91
35	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581.	1.5	91
36	New treatments for SLE: cell-depleting and anti-cytokine therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 859-878.	1.4	83

#	ARTICLE	IF	CITATIONS
37	SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. <i>Arthritis Research</i> , 2003, 5, 172.	2.0	80
38	Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. <i>Rheumatology</i> , 2013, 52, 1070-1076.	0.9	77
39	Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. <i>European Journal of Radiology</i> , 2007, 62, 437-443.	1.2	76
40	Glucocorticoid Dosages and Acute Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	2.9	74
41	Severe infections in plasmapheresis-treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 41, 414-420.	6.7	71
42	Gout. <i>Deutsches Arzteblatt International</i> , 2009, 106, 549-55.	0.6	71
43	Does Mixed Connective Tissue Disease Exist? Yes. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 411-420.	0.8	70
44	EULAR/ACR classification criteria for SLE. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, S14-S17.	1.6	69
45	Listeria -Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2537-2541.	1.8	67
46	Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. <i>Rheumatology</i> , 2014, 53, 1630-1638.	0.9	66
47	Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. <i>Journal of Rheumatology</i> , 2002, 29, 1430-6.	1.0	65
48	Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. <i>Arthritis and Rheumatism</i> , 2007, 57, 1287-1295.	6.7	61
49	Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1194-1199.	0.5	55
50	Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. <i>Arthritis Care and Research</i> , 2019, 71, 471-481.	1.5	55
51	Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 411-419.	1.0	52
52	Classifying and diagnosing systemic lupus erythematosus in the 21st century. <i>Rheumatology</i> , 2020, 59, v4-v11.	0.9	52
53	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.	2.2	52
54	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.5	51

#	ARTICLE	IF	CITATIONS
55	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1488-1494.	1.5	48
56	Response to: "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus" by Aringer et al. by Cui et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e166-e166.	0.5	47
57	Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. <i>Arthritis and Rheumatism</i> , 2009, 61, 21-28.	6.7	46
58	Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis " A Multi-perspective Consensus Study. <i>Zeitschrift Fur Orthopadie Und Unfallchirurgie</i> , 2017, 155, 539-548.	0.4	46
59	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
60	Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1039-1047.	2.9	44
61	Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. <i>Rheumatology International</i> , 2018, 38, 569-577.	1.5	43
62	Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. <i>Lupus</i> , 2021, 30, 431-438.	0.8	43
63	New Criteria for Lupus. <i>Current Rheumatology Reports</i> , 2020, 22, 18.	2.1	37
64	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
65	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
66	Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). <i>Journal of Rheumatology</i> , 2012, 39, 2153-2156.	1.0	32
67	Interferon signals and monocytic sensitization of the interferon- $\beta$ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 400-408.	6.7	31
68	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
69	Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. <i>Arthritis Care and Research</i> , 2017, 69, 58-66.	1.5	30
70	Characterization and Analysis of the ProximalJanus Kinase 3Promoter. <i>Journal of Immunology</i> , 2003, 170, 6057-6064.	0.4	29
71	The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. <i>International Journal of Molecular Sciences</i> , 2017, 18, 380.	1.8	29
72	Immunoabsorption as a rescue therapy in systemic lupus erythematosus: considerations on safety and efficacy. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 716-724.	1.0	28

#	ARTICLE	IF	CITATIONS
73	Innate immune processes in lupus erythematosus. <i>Clinical Immunology</i> , 2013, 147, 216-222.	1.4	28
74	Response to: "European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view" by Infantino <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e189-e189.	0.5	28
75	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1820-1826.	1.5	28
76	Mixed connective tissue disease: what is behind the curtain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 1037-1049.	1.4	27
77	Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1986-1990.	0.5	25
78	New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis " Implications from the prospective multicenter VADERA II study. <i>PLoS ONE</i> , 2019, 14, e0217412.	1.1	25
79	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 671-676.	2.9	24
80	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	0.9	24
81	Immunoabsorption in Autoimmune Diseases Affecting the Kidney. <i>Seminars in Nephrology</i> , 2017, 37, 478-487.	0.6	23
82	A 3-Day Delay in Synovial Fluid Crystal Identification Did Not Hinder the Reliable Detection of Monosodium Urate and Calcium Pyrophosphate Crystals. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 241-245.	0.5	22
83	New classification criteria for systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020, 32, 590-596.	2.0	21
84	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012, 14, R2.	1.6	19
85	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
86	A bridge between interferon-alpha and tumor necrosis factor in lupus. <i>Journal of Rheumatology</i> , 2008, 35, 1473-6.	1.0	16
87	Systemic Lupus Erythematosus Classification and Diagnosis. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 501-511.	0.8	15
88	A glimpse into the future of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	1.2	14
89	Vaccination under TNF blockade - less effective, but worthwhile. <i>Arthritis Research and Therapy</i> , 2012, 14, 117.	1.6	13
90	Lots of autoantibodies equal lupus?. <i>Arthritis Research and Therapy</i> , 2013, 15, 102.	1.6	13

#	ARTICLE	IF	CITATIONS
91	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
92	Immunoabsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. <i>Diabetes Care</i> , 2018, 41, e23-e24.	4.3	13
93	Treat to Target in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 537-548.	0.8	13
94	Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib. <i>British Journal of Dermatology</i> , 2022, 187, 432-435.	1.4	13
95	Role of tumor necrosis factor $\gamma$ and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: Comment on the editorial by Pisetsky. <i>Arthritis and Rheumatism</i> , 2001, 44, 1721-1722.	6.7	11
96	Engineering Anticancer T Cells for Extended Functional Longevity. <i>Annals of the New York Academy of Sciences</i> , 2004, 1019, 178-185.	1.8	11
97	Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1 $\alpha$ -related protein in patients with rheumatic diseases: Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. <i>Arthritis and Rheumatism</i> , 2008, 58, 1226-1236.	6.7	11
98	Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell Profiling. <i>Arthritis and Rheumatology</i> , 2019, 71, 817-828.	2.9	11
99	Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. <i>Lupus Science and Medicine</i> , 2021, 8, e000526.	1.1	11
100	Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S71-4.	0.4	11
101	Advances in SLE classification criteria. <i>Journal of Autoimmunity</i> , 2022, 132, 102845.	3.0	11
102	The Janus Faces of Allopurinol—Allopurinol Hypersensitivity Syndrome. <i>American Journal of Medicine</i> , 2008, 121, e3-e4.	0.6	9
103	Understanding deficient elimination of uric acid. <i>Lancet, The</i> , 2008, 372, 1929-1930.	6.3	9
104	Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma. <i>Case Reports in Medicine</i> , 2011, 2011, 1-3.	0.3	9
105	Safety of off-label biologicals in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 243-251.	1.0	9
106	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
107	TNF-alpha Blockade with Infliximab in a Patient with Lupus Erythematosus Profundus. <i>Acta Dermato-Venereologica</i> , 2012, 92, 401-403.	0.6	8
108	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). <i>Rheumatology</i> , 2021, 60, 5318-5328.	0.9	8



#	ARTICLE	IF	CITATIONS
109	New lupus criteria: a critical view. <i>Current Opinion in Rheumatology</i> , 2021, 33, 205-210.	2.0	8
110	Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 135-144.	1.3	8
111	Relevant Concepts of Functioning for Patients With Systemic Lupus Erythematosus Identified in a Delphi Exercise of Experts and a Literature Review. <i>Arthritis Care and Research</i> , 2014, 66, 1895-1904.	1.5	7
112	Chemosensory function is decreased in rheumatoid arthritis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1675-1680.	0.8	7
113	Periodic fever syndromes—a clinical overview. <i>Vienna Clinical Weekly</i> , 2004, 31, 8-12.	0.9	7
114	Mixed Lymphohematopoietic Chimerism and Response in Wegener's Granulomatosis. <i>New England Journal of Medicine</i> , 2010, 362, 2431-2432.	13.9	6
115	Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells. <i>Atherosclerosis Supplements</i> , 2017, 30, 141-148.	1.2	6
116	FRI0193â€¦2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
117	Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Bossuyt<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e194-e194.	0.5	6
118	Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon. <i>Autoimmunity</i> , 2007, 40, 315-321.	1.2	5
119	Systemic sclerosis phase III clinical trials: Hope on the horizon?. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 193-200.	1.0	5
120	Glucocorticoid dosing and relapses in giant cell arteritisâ€”a single centre cohort study. <i>Rheumatology</i> , 2022, 61, 1997-2005.	0.9	5
121	Janus kinase inhibitors clear to land. <i>Rheumatology</i> , 2018, 57, 1131-1132.	0.9	4
122	Difference between SLE classification and diagnosis and importance of attribution. Response to: “Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?”â€™ by Chi et al. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrhumdis-2019-216338.	0.5	4
123	Endpoints for randomised controlled trials in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 147-51.	0.4	4
124	Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 213-8.	0.4	4
125	Parvovirus infection in early arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 207-13.	0.4	4
126	High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 561-562.	0.5	3



#	ARTICLE	IF	CITATIONS
127	Tocilizumab in the treatment of giant cell arteritis. <i>Immunotherapy</i> , 2018, 10, 465-472.	1.0	3
128	Response to: "New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion" by Sacre <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e191-e191.	0.5	3
129	Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 713-714.	0.5	3
130	Response to: "Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?" by Teng <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e23-e23.	0.5	3
131	Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2. <i>Lancet Rheumatology</i> , The, 2021, 3, e538-e540.	2.2	3
132	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3
133	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 696-697.	1.5	2
134	Severe infections in plasmapheresis-treated systemic lupus erythematosus. , 1998, 41, 414.		2
135	Response to: "Correspondence on "Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities" by Ronnelid <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219314.	0.5	2
136	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. <i>Arthritis Care and Research</i> , 0, , .	1.5	2
137	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 319-328.	0.4	2
138	Effector Mechanisms in Autoimmunity. , 2014, , 311-318.		1
139	Response to: "New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS" by Assan <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, , annrheumdis-2019-216250.	0.5	1
140	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 695-696.	2.9	1
141	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria" documenting progress in lupus. <i>Rheumatology</i> , 2020, 60, 2976-2978.	0.9	1
142	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
143	Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101672.	1.4	1
144	Diagnosis and Classification of Systemic Lupus Erythematosus. , 2021, , 51-66.		1

#	ARTICLE	IF	CITATIONS
145	Response to: "Role of ANA testing in the classification of patients with systemic lupus erythematosus" by Pisetsky et al. Annals of the Rheumatic Diseases, 2021, 80, e125-e125.	0.5	1
146	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 319-328.	0.4	1
147	Targeted Therapies "Many Ways to (the Peace of) Rome. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 200-206.	0.5	0
148	Clinical applications of IFN- $\gamma$ blockade in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2009, 4, 617-619.	0.3	0
149	Decreased interleukin-6 receptor (IL-6R $\alpha$ ) and increased signal transducer and activator of transcription 3 (Stat3) phosphorylation in rheumatoid arthritis (RA) are reversed by IL-6R $\alpha$ blockade. Annals of the Rheumatic Diseases, 2012, 71, A8.1-A8.	0.5	0
150	Essential and Optional Drugs for Rheumatic Diseases. Handbook of Systemic Autoimmune Diseases, 2018, , 77-96.	0.1	0
151	How Should We Consider Lupus Without Antinuclear Antibodies?. Arthritis Care and Research, 2019, 71, 853-854.	1.5	0
152	SAT0163...LOW CARDIOVASCULAR EVENT RATE DURING TOCILIZUMAB TREATMENT IN THE NON-INTERVENTIONAL STUDY ICHIBAN. , 2019, , .		0
153	THU0158...IMPAIRED OLFACTORY FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
154	FRI0192...A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
155	Response to: "Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus" by Wang et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216807.	0.5	0
156	Effector Mechanisms in Autoimmunity. , 2020, , 319-329.		0
157	Treat-to-Target bei systemischem Lupus erythematosus. Karger Kompass Autoimmun, 2020, 2, 45-52.	0.0	0
158	Reply. Arthritis and Rheumatology, 2020, 72, 860-861.	2.9	0
159	Reply. Arthritis and Rheumatology, 2020, 72, 1404-1404.	2.9	0
160	Regulatory T cells have anti-inflammatory effects by diluting TNF. Future Rheumatology, 2008, 3, 231-234.	0.2	0
161	Who will respond to type I interferon receptor blockade in SLE?. Lancet Rheumatology, The, 2022, , .	2.2	0
162	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clinical and Experimental Rheumatology, 2021, , .	0.4	0